Skip to content
DataLookout
Menu

NCT05569681

Two Different Regimens of Bemiparin as a Thromboprophylaxis in Morbidly Obese Surgical Patients

StatusCompleted
PhaseNot applicable
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 9 versions: 8 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Trial completed Show 4 more changesShow less
    • Final enrollment: 1248 participants (planned 2400)
    • Primary completion date changed from estimate of Sep 25, 2026 to Oct 20, 2026
    • Study completion date changed from estimate of Oct 2, 2026 to Oct 23, 2026
    • Site details revised
  2. Notable Eligibility criteria shortened, about 6 words
    • Primary completion date: Sep 2, 2026 to Sep 25, 2026
  3. Notable Primary completion date: Feb 2, 2026 to Sep 2, 2026
    • Study completion date: Apr 2, 2026 to Oct 2, 2026
    v7
  4. Minor Study description expanded, about 91 wordsv6
  5. Notable Eligibility criteria shortened, about 2 wordsv5
Show 2 earlier versionsHide 2 earlier versions
  1. Notable Trial status: Not Yet Recruiting to Recruitingv3 Show 4 more changesShow less
    • Primary completion date: Feb 2, 2025 to Feb 2, 2026
    • Study completion date: Apr 2, 2025 to Apr 2, 2026
    • Start date changed from estimate of Dec 2, 2022 to Jan 7, 2023
    • Site details revised
  2. Notable Primary endpoint revisedv2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Number of participants with VTE events (Deep vein thrombosis or pulmonary embolism)
Timeframe: up to 30 days after surgery

Secondary (1)

Side effects of both Bemiparin doses

Arms and interventions

Bemiparin 3500 IUActive comparator

Bemiparin sodium 3,500 IU anti Xa/0.2 ml solution for injection in the pre-filled syringe will be provided for each patient in one group; subcutaneously 6 hours after the surgery(orthopedic and non-orthopedic) and then daily for up to 10 days for moderate and high - risk group and for 30 days in very high risk-group patients according to Caprinin risk classification for venous thromboembolism. Other Name: Hibor; Laboratories Rovi Pharmaceuticals

Bemiparin 5000 IUActive comparator

Bemiparin sodium 5000 IU anti Xa/0.2 ml solution for injection in the pre-filled syringe will be provided for each patient in one group; subcutaneously 6 hours after the surgery(orthopedic and non-orthopedic) and then daily for up to 10 days for moderate and high - risk group patients and 30 days in very high-risk group surgical patients according to Caprinin risk classification for venous thromboembolism. Other Name: Hibor; Laboratories Rovi Pharmaceuticals

Drugs: Bemiparin 3500, Bemiparin 5000 IU

Sites

1 site in 1 country

  • Hawler Medical universityErbil, Kurdistan Region, Iraq